Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Coherus BioSciences, Inc.

Coherus BioSciences develops immuno-oncology therapies aimed at cancer treatment, including FDA-approved medicines such as LOQTORZI. It focuses on improving patient outcomes through a diversified pipeline of drug candidates.

Metric
Company Name	Coherus BioSciences, Inc.
Symbol	CHRS
MSH ID	COM:COHERUS
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	249
Website	coherus.com
LinkedIn
Founders

Metric
Market Cap	164.06M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	257.24M
Revenue (LTM)
Revenue (NTM)
Gross Profit	94.46M
EBITDA	-189.41M
Operating Income	-193.20M
Net Income	-237.89M
EPS	-2.53
Diluted EPS	-2.53
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.50
Operating Profit Margin	-0.51
EBITDA Margin	-0.74
Net Profit Margin	-0.10
Return on Equity	1.36
Return on Assets	-0.04
Return on Capital Employed	-0.68

COM:COHERUS

Coherus BioSciences

Last Close

1.10

22/11 21:00

Market Cap

164.06M

Beta: -

Volume Today

2.69M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.89
P/B Ratio	-1.49
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.02
EV Multiple	0.77

Metric
Days Sales Outstanding	374.41
Days Payables Outstanding	152.76
Days Inventory Outstanding	146.93
Operating Cycle	512.42
Cash Conversion Cycle	432.10
Asset Turnover	0.46

Metric
Operating Cash Flow	-174.88M
Free Cash Flow	-175.17M
Cash Flow to Debt	-0.18
Operating Cash Flow/Sales	-0.18
Free Cash Flow Yield	-1.16

Metric
Cash & Equivalents	102.89M
Accounts Receivable	-150.68M
Inventory	62.60M
Goodwill	943K
Debt to Capitalization	1.69
Debt to Assets	0.82
Current Ratio	1.85
Quick Ratio	1.14

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.21
R&D to Revenue	0.53
SG&A to Revenue